Related Experiment Video
Updated: Aug 13, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Heart failure: highlights from new consensus guidelines
1Department of Cardiology, Cleveland Clinic, USA.
Insights
New heart failure guidelines recommend identifying patients for therapy, measuring ejection fraction via echocardiogram, and initiating ACE inhibitor and beta-blocker treatment for systolic dysfunction. Spironolactone may reduce mortality in heart failure patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure management guidelines are evolving.
- Systolic dysfunction requires specific therapeutic approaches.
Purpose of the Study:
- To summarize new guidelines for managing heart failure.
- To outline recommended diagnostic and therapeutic strategies.
Main Methods:
- Guideline review and synthesis.
- Identification of key recommendations for patient management.
Main Results:
- Ejection fraction measurement via echocardiogram is crucial.
- Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are recommended for systolic dysfunction.
- Spironolactone may reduce mortality in heart failure.
Conclusions:
- Early identification and targeted therapy improve heart failure outcomes.
- ACE inhibitors, beta-blockers, and potentially low-dose spironolactone are key in managing systolic heart failure.
- Further research is needed on angiotensin II receptor blockers.
Abstract:
New guidelines for managing heart failure urge physicians to identify patients likely to benefit from therapy, obtain an echocardiogram to measure the ejection fraction, and, in patients with systolic dysfunction (i.e., an ejection fraction < or = 40%), institute therapy with an angiotensin-converting enzyme (ACE) inhibitor and a beta-blocker if at all possible. Digoxin and diuretics can relieve symptoms but do not affect the mortality rate. Spironolactone in low nondiuretic doses may reduce mortality when added to baseline drug regimens. The proper role of angiotensin II receptor blocking agents has yet to be determined.
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions

